Chemours Stock Rockets 22% With 5-Day Winning Streak
Chemours (CC) – a provider of performance chemicals and titanium dioxide pigments – hit a 5-day winning streak, with cumulative gains over this period amounting to 22%. The company’s market cap has surged by about $587 Mil over the last 5 days and currently stands at $3.3 Bil.
Is this opportunity or trap? There is a lot to fear in CC stock given its overall Very Weak operating performance and financial condition. In addition, keeping in mind its High valuation, we think that the stock is Very Unattractive (For details, see Buy or Sell CC).
But here is the interesting part. You are reading about this 22% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Palantir At 80x Earnings: What Revenue Growth Rate Justifies The Valuation?
- Should You Pay Attention To Chevron Stock’s Momentum?
- What Is Happening With Caterpillar Stock?
- What Can Trigger Microsoft Stock’s Slide?
- Is Microsoft Stock A Trap Or A Missed Opportunity?
- Earn 9.6% Today or Buy BSX 30% Cheaper – It’s a Win-Win
The following table summarizes the return for CC stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CC | S&P 500 |
|---|---|---|
| 1D | 0.1% | -1.7% |
| 5D (Current Streak) | 22.0% | -2.1% |
| 1M (21D) | 24.7% | -7.8% |
| 3M (63D) | 80.9% | -8.1% |
| YTD 2026 | 84.1% | -7.0% |
| 2025 | -27.6% | 16.4% |
| 2024 | -44.0% | 23.3% |
| 2023 | 6.5% | 24.2% |
However, big gains can follow sharp reversals – but how has CC behaved after prior drops? See CC Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 30 S&P constituents with 3 days or more of consecutive gains and 75 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 3 | 43 |
| 4D | 10 | 23 |
| 5D | 16 | 5 |
| 6D | 0 | 1 |
| 7D or more | 1 | 3 |
| Total >=3 D | 30 | 75 |
Key Financials for Chemours (CC)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $5.8 Bil | $5.8 Bil |
| Operating Income | $421.0 Mil | $-28.0 Mil |
| Net Income | $69.0 Mil | $-386.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $1.5 Bil | $1.3 Bil |
| Operating Income | $93.0 Mil | $-5.0 Mil |
| Net Income | $60.0 Mil | $-61.0 Mil |
While CC stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.